Related Experiment Videos
Single-enantiomer drugs: elegant science, disappointing effects
Peter Mansfield1, David Henry, Anne Tonkin
1Department of General Practice, University of Adelaide, Adelaide, South Australia, Australia.
Clinical Pharmacokinetics
|April 15, 2004
Summary
Chiral switching, marketing single enantiomer drugs, offers minimal clinical benefits over racemic forms. Higher prices for these newer drugs are often not justified by improved efficacy or safety, driven by patent protection and perceived superiority.
Area of Science:
- Pharmacology
- Drug Development
- Medicinal Chemistry
Background:
- Many established drugs exist as racemic mixtures.
- Chiral switching involves developing single enantiomer versions of existing racemic drugs.
- This strategy is often promoted for improved clinical outcomes.
Purpose of the Study:
- To evaluate the clinical evidence and pricing of recently marketed single enantiomer drugs.
- To assess the claimed benefits of chiral switching compared to racemic counterparts.
- To analyze the economic implications and price sustainability of single enantiomer drugs.
Main Methods:
- Review of clinical trial data for efficacy, pharmacokinetics, and toxicity.
- Price comparison between single enantiomer drugs and their racemic alternatives.
- Analysis of market dynamics, including patent protection and generic availability.
Main Results:
- Claims of enhanced efficacy for single enantiomer drugs were often based on non-equivalent dosing and showed minor clinical relevance.
- Single enantiomer versions (esomeprazole, levosalbutamol) were priced higher than their racemic forms.
- Price premiums are expected to persist due to market factors, irrespective of clinical advantages.
Conclusions:
- Chiral switching does not consistently provide significant clinical benefits over racemic drugs.
- The higher cost of single enantiomer drugs is often not supported by robust clinical evidence.
- Market exclusivity and promotional strategies maintain price premiums for single enantiomer drugs.